BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 15860267)

  • 21. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
    Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
    Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice.
    Brünner N; Bronzert D; Vindeløv LL; Rygaard K; Spang-Thomsen M; Lippman ME
    Cancer Res; 1989 Mar; 49(6):1515-20. PubMed ID: 2924304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.
    Ju YH; Doerge DR; Allred KF; Allred CD; Helferich WG
    Cancer Res; 2002 May; 62(9):2474-7. PubMed ID: 11980635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
    Osborne CK; Hobbs K; Clark GM
    Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
    Nabha SM; Glaros S; Hong M; Lykkesfeldt AE; Schiff R; Osborne K; Reddy KB
    Oncogene; 2005 Apr; 24(19):3166-76. PubMed ID: 15735693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.
    Naundorf H; Becker M; Lykkesfeldt AE; Elbe B; Neumann C; Büttner B; Fichtner I
    Br J Cancer; 2000 Jun; 82(11):1844-50. PubMed ID: 10839300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
    Zhao W; Zhang Q; Kang X; Jin S; Lou C
    Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.
    Osipo C; Meeke K; Liu H; Cheng D; Lim S; Weichel A; Jordan VC
    Cancer Res; 2005 Sep; 65(18):8504-13. PubMed ID: 16166331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
    Robinson SP; Jordan VC
    Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry.
    Sarkaria JN; Gibson DF; Jordan VC; Fowler JF; Lindstrom MJ; Mulcahy RT
    Cancer Res; 1993 Sep; 53(18):4413-7. PubMed ID: 8364937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice.
    Koibuchi Y; Iino Y; Uchida T; Andoh T; Horii Y; Nagasawa M; Horiguchi J; Maemura M; Takei H; Yokoe T; Morishita Y
    Oncol Rep; 2000; 7(1):135-40. PubMed ID: 10601607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
    Wolf DM; Jordan VC
    Breast Cancer Res Treat; 1994; 31(1):117-27. PubMed ID: 7981452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
    Zhang L; Kharbanda S; Hanfelt J; Kern FG
    Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.